Drugs / STEBVax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00974935 | Feb 2011 → Mar 2015 | staphylococcal toxic-shock syndrome | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STEBVax | “used as a potential parenteral vaccine named STEBVax” PMID 27707765 ↗ Dec 2016 |
| Known as | STEBVax vaccine | “STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection” NCT00974935 ↗ |
| Modality | Vaccine | “used as a potential parenteral vaccine named STEBVax” PMID 27707765 ↗ Dec 2016 |
| Route | Intramuscular | “STEBVax will be administered as a single 0.5 mL intramuscular injection” NCT00974935 ↗ |